Phase 2 N=77 Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 15; 30 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=660 Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children
Influenza
Primary: Receipt of 2nd Dose of the Influenza Vaccine. — 72.7; 66.7; 57.1 percentage of participants
N/A N=89 Internet Treatment for Weight Loss in Primary Care
Overweight · Obese
Primary: Body Weight in Pounds. — -3.1; -3.4; 0.1 pounds
N/A N=13 Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Obesity-induced Hyperfiltration
Primary: Change in GFR (ml/Min) — 151; 152; 120; 150 ml/min
Phase 2 N=66 The Effects of Lycopene on High Risk Prostatic Tissue
Intraepithelial Prostatic Neoplasia · Prostatic Neoplasms
Primary: Tissue Biomarkers
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
Phase 3 N=322 Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
Epilepsy
Primary: Percentage of Subjects on Lacosamide (LCM) Monotherapy at Any Time Between Visit 1 and End of Study — 292 Participants
Phase 4 N=229 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 14; 7; 1; 171 participant exams — p=0.8516
Phase 2 N=41 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST) — 3; 1 participants
Phase 1 N=84 Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Relapsed Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6; 6; 8; 6 participants
Phase 3 N=1,761 Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal
Influenza
Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match) — 17.9; 18.0 percentage of participants — p=0.996
N/A N=1,099 Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure
Hypertension
Primary: Change in Urinary Sodium Excretion (UNaV) — 11.8; 15.2 pg/ml
Phase 4 N=20 Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week — 0.069; 0.010; 0.121; 0.023 Liters
N/A N=47 Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
Sarcoma · Chemotherapy-induced Nausea and Vomiting · Effects of Chemotherapy
Primary: Complete Response — 17; 10; 50 percentage of participants
Phase 3 N=45 A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome (FCS)
Primary: Percent Change in Fasting Triglycerides From Baseline to 12 Weeks — 45.6; 3.7; -13.9 percent change — p=0.0538